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Abstract
Introduction The ability of dendritic cells (DCs) to take up whole
tumor cells and process their antigens for presentation to T cells
('cross-priming') is an important mechanism for induction of
tumor specific immunity.
Methods  In vitro generated DCs were loaded with killed
allogeneic breast cancer cells and offered to autologous naïve
CD8+ T cells in 2-week and/or 3-week cultures. CD8+ T cell
differentiation was measured by their capacity to secrete
effector cytokines (interferon-γ) and kill breast cancer cells.
Specificity was measured using peptides derived from defined
breast cancer antigens.
Results We found that DCs loaded with killed breast cancer
cells can prime naïve CD8+ T cells to differentiate into effector
cytotoxic T lymphocytes (CTLs). Importantly, these CTLs primed
by DCs loaded with killed HLA-A*0201- breast cancer cells can
kill HLA-A*0201+ breast cancer cells. Among the tumor specific
CTLs, we found that CTLs specific for HLA-A2 restricted
peptides derived from three well known shared breast tumor
antigens, namely cyclin B1, MUC-1 and survivin.
Conclusion This ability of DCs loaded with killed allogeneic
breast cancer cells to elicit multiantigen specific immunity
supports their use as vaccines in patients with breast cancer.
Introduction
Despite declining mortality rates, breast cancer ranks second
among cancer related deaths in women. In the USA alone, it is
estimated that more than 200,000 new cases of breast cancer
will be diagnosed yearly, with that about 40,000 patients will
die from breast cancer [1]. Therefore, there is a need to
develop novel therapeutic approaches to improve survival
rates among patients with breast cancer.
Evidence is accumulating that naturally occurring immunity is
present in patients with breast cancer against tumor associ-
ated antigens such as HER-2/neu [2,3] and cdr2 [4], as well
as the antigens investigated here, namely MUC-1 [5,6], cyclin
B1 [7] and survivin [8]. Several clinical studies have now dem-
onstrated that immunity against tumor antigens can also be
boosted or elicited in cancer patients by vaccination, most
recently through the use of tumor antigen loaded dendritic
cells (DCs) [9-13]. For example, in a recently reported trial
[14], two out of ten patients with breast/ovarian cancer vacci-
nated with HER-2/neu or MUC-1 peptide-pulsed monocyte-
derived DCs generated cytotoxic T lymphocytes (CTLs) that
were able to kill HLA-A*0201 cell lines expressing these anti-
gens. The optimal source of tumor antigens for loading of ex
vivo generated DCs is yet to be determined [15]. In particular,
strategies that allow tumor antigen presentation across HLA
haplotypes are needed, and several have been undergoing
investigation. These include loading DCs with recombinant
proteins, killed tumor cells [4,16-18], tumor RNA [19,20] and
viral vectors that encode tumor antigens [21], and fusing DCs
with tumor cells [22]. In prostate cancer [17] and in melanoma
[18], we previously showed that DCs loaded with killed alloge-
neic tumor cells cross-prime naïve CD8+ T cells to differentiate
into CTLs specific for shared tumor antigens.
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In breast cancer, we previously demonstrated that DCs loaded
with killed breast cancer cells can induce CTLs that can kill
those breast cancer cells [23]. However, we were unable to
determine the antigen specificity of these CTLs. In an exten-
sion of that work, here we demonstrate that DCs loaded with
killed allogeneic breast cancer cells can prime naïve CD8+ T
cells to differentiate into tumor antigen specific CTLs by con-
firming their specificity for three known breast cancer anti-
gens: cyclin B1, MUC-1, and survivin.
Materials and methods
Media and reagents
Complete RPMI-1640 was supplemented with 10% heat-
inactivated fetal calf serum (Hyclone, Logan, UT, USA) for
DCs and 10% human serum AB (Gem cell) for T cell cultures.
Cytokines used included granulocyte-macrophage colony-
stimulating factor (100 ng/ml; Immunex, Amgen Thousand
Oaks, CA, USA), IL-4 (25 ng/ml; R&D Systems, Minneapolis,
MN, USA), soluble CD40 ligand (200 ng/ml; R&D Systems),
IL-2 (10 IU/ml; R&D Systems), and IL-7 (10 IU/ml; R&D Sys-
tems). Betulinic acid (Sigma-Aldrich, St. Louis, MO, USA) was
used at 10 mg/ml. Cyclin B1 peptide CB9 (sequence
AKYLMELTM) was synthesized at the University of Pittsburgh
Cancer Institute Peptide Synthesis facility. MUC-1 peptides
D6 (sequence LLLTVLTVV) and PSA1 (sequence FLTP-
KKLQCV) were purchased from Bio-Synthesis (TX, Lewisville,
USA). The surviving peptide library was synthesized at the
Rockefeller University.
Cell lines
Breast cancer cell lines T47D, Hs578T, MCF-7, natural killer
cell target K562 and HLA-A*0201+ T2 cells, which are targets
for CTLs, were obtained from the American Type Culture Col-
lection (Manassas, VA, USA). The Me275 melanoma cell line
was a kind gift from Drs J-C Cerottini and D Rimoldi. All cell
lines were maintained in complete RPMI1640 (Gibco, Invitro-
gen, Carlsbad, California, USA). For loading of DCs, T47D
and Hs578T cells were killed by incubation with betulinic acid
(Sigma-Aldrich), as described previously [18]. MCF-7 cells
were killed by gamma irradiation (80 Gy) and 24 hours of
exposure to tumor necrosis factor-α (100 ng/ml; R&D
Systems).
Generation of cytotoxic T lymphocytes
Naïve HLA-A*0201+ CD8+ T cells (autologous to the DCs)
were depleted of other cells using anti-CD4, anti-CD14, anti-
CD16, anti-CD19, anti-CD56, and anti-glycophorin A
microbeads (Miltenyi, Auburn, CA, USA) and sorted based on
CD8+CD45RA+CCR7+CD45RO- phenotype. DCs were gen-
erated from the adherent fraction of peripheral blood mononu-
clear cells by culturing for 6 days in complete RPMI1640
supplemented with granulocyte-macrophage colony-stimulat-
ing factor and IL-4, loaded with killed tumor cells, sorted, and
used as stimulators of autologous purified naïve CD8+ T cells
at a 1:10 ratio. Soluble CD40 ligand was added to induce DC
maturation, and IL-7 (10 IU/ml in weeks 1, 2, and 3) and IL-2
(10 IU/ml in weeks 2 and 3) for T cell expansion. T cells were
restimulated weekly with tumor cell loaded DCs.
51Cr cytotoxicity assay
For use as targets, T2 cells were pulsed overnight with 10 μg/
ml of various peptides, labeled with 51Cr (NEN Life Science
Products, Boston, Massachusetts, USA) and co-cultured with
CTLs for 4 hours. Specific lysis was calculated using the fol-
lowing formula (where cpm is the counts/minute): % release =
100 × (cpm experiment – cpm spontaneous release)/(cpm
maximum release – cpm spontaneous release). For the mAb
blocking assays, anti-HLA-A, HLA-B and HLA-C antibody
(W6/32; DAKO, Carpenteria, CA, USA; 5 μg/ml) or an irrele-
vant (control) antibody was added to the target cells 30 min-
utes before the addition of CTLs and left throughout the
culture period.
Tumor inhibition assay
Target tumor cell lines were suspended at a concentration of
5 × 104/ml with RPMI1640 medium containing 10% AB
serum and the CTLs at 106/ml. Targets cells and CTLs were
co-incubated in 96-U bottom plates (Costar, Corning, Sigma-
Aldrich) for 24 hours. The numbers of live and dead tumor cells
were determined using trypan blue exclusion.
Intracellular cytokine staining
Primed and boosted T cells were cultured for 6 hours with
DCs loaded with 15-mer peptides representing survivin pep-
tide library. At 2 hours of stimulation, Golgi-stop™ (BD
Pharmingen, San Diego, CA, USA) was added to the culture.
At 6 hours of stimulation, cells were harvested and first stained
with CD3-PerCP and CD8-APC mAbs, fixed and permeabi-
lized with BD Cytofix/Cytoperm™ solution (BD), and then
stained with anti-IFN-γ PE (BD Pharmingen).
T cell restimulation assay
CD8+ T cells that had undergone two stimulations with DCs
loaded with killed breast cancer cells were co-incubated with
autologous DCs pulsed with the survivin peptide library at a
10:1 ratio. The T cells were analyzed after an additional 5 to 7
days of culture by intracellular cytokine staining, as described
above.
Statistical analysis
Nonparametric Kruskal-Wallis analysis of variance was used
as indicated to assess the killing of three different target cells.
P < 0.05 was considered statistically significant.
Results
Development of breast cancer specific CD8+ T cells 
through cross-priming
We used HLA-A*0201+ monocyte-derived DCs loaded with
killed allogeneic breast cancer cells to prime in vitro autolo-
gous naïve CD45RA+CCR7+CD45RO-CD8+  T cells. TheAvailable online http://breast-cancer-research.com/content/8/6/R65
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priming and weekly restimulations were performed with the
addition of soluble CD40 ligand, and the T cells were main-
tained in the presence of 10 U/ml of cytokines IL-7 and IL-2.
As shown in Figure 1, after 3 weeks of culture naïve CD8+ T
cells differentiated into effector cells, as measured by expres-
sion of IFN-γ, granzymes A and B, and perforin (Figure 1a).
This differentiation was observed in cultures stimulated with
control DCs as well as antigen loaded DCs, but the antigen
loaded DCs stimulated greater expansion of effector CD8+ T
cells expressing granzymes A and B (Figure 1b to 1d). A pos-
sible explanation for the antigen-independent differentiation
seen in several independent experiments using T cells from
three different donors could come from the addition of T cell
cytokines such as IL-7 and IL-2 to support CD8+ T cell priming.
The cytotoxic effector function of antigen-primed CD8+ T cells
against breast cancer cells was analyzed in a 4-hour 51Cr
release assay. As shown in Figure 2a, CD8+ T cells cultured
Figure 1
DCs loaded with killed breast cancer cells induce differentiation of naïve CD8+ T cells into effector cells DCs loaded with killed breast cancer cells induce differentiation of naïve CD8+ T cells into effector cells. Sorted naïve CD8+ T were cultured for 3 
weeks with autologous DCs either (a) not loaded or (b) loaded with killed breast cancer cells. The cultures were restimulated twice. Intracytoplas-
mic staining and flow cytometry are given for the indicated effector molecules. Shown is one representative experiment from three with T cells from 
three different healthy donors. Percentage of CD8+ T cells expressing (c) indicated cytokines or (d) effector molecules in cultures with unloaded 
(black bars) and loaded (gray bars) DCs. DC, dendritic cell; GM-CSF, granulocyte-macrophage colony-stimulating factor; Gr, granzyme; IFN, inter-
feron; IL, interleukin.Breast Cancer Research    Vol 8 No 6    Saito et al.
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with HLA-A*0201+  DCs loaded with killed HLA-A*0201+
MCF7 breast cancer cells were able to kill MCF7 cells but not
natural killer sensitive K562 cells. Such effective priming of
tumor specific CD8+ T was achieved with naïve T cells from
three different donors. Tumor cell lysis could be abolished by
pretreatment of the target MCF7 cells with anti-MHC class I
antibody, thus confirming that induction of HLA class I
restricted CTLs was taking place in these cultures (Figure 2b).
To confirm that cross-priming had occurred, naïve HLA-
A*0201+ CD8+ T cells were exposed to three stimulations with
autologous HLA-A*0201+  DCs loaded with HLA-A*0201-
breast cancer cell lines T47D or Hs578T and tested on HLA-
A*0201+ MCF-7 target cells in a 4-hour 51Cr release assay
(Figure 3a and 3b) and a 24-hour tumor inhibition assay [24]
(Figure 3c). As shown in Figure 3, CTLs primed in these cul-
tures could kill HLA-A*0201+ MCF7 breast cancer cells not
used in the priming, thus demonstrating cross-priming against
antigens shared between the priming and the target breast
cancer cell lines (Figure 3a and 3b). These antigens were
mostly breast cancer specific, as further demonstrated by the
inability of the breast cancer primed CTLs to kill HLA-A*0201+
Me275 melanoma cells (Figure 3a and 3b). These results were
obtained with CD8+ T cells isolated from four different healthy
donors in four independent experiments. These data clearly
show that DCs loaded with killed allogeneic breast cancer
cells can cross-prime naïve CD8+ T cells to differentiate into
CTLs specific for antigens shared between breast cancer cell
lines.
Specificity of breast cancer cross-primed cytotoxic T 
lymphocytes for defined shared tumor antigens
The desired objective of loading DCs with killed breast cancer
cells was to prime a polyclonal population of antigen specific
CTLs. To determine whether this was indeed the case, we
tested the primed CTL cultures for the presence of T cells spe-
cific for three well known tumor antigens expressed in breast
cancers, namely cyclin B1, MUC-1 and survivin.
Cyclin B1-specific cytotoxic T lymphocytes
The discovery of cyclin B1 as a potential target for T cells in
patients with breast as well as head and neck cancers
expanded the spectrum of defined tumor antigens expressed
in breast cancer [7]. Among the breast cancer cells we used,
T47D cells demonstrated the greatest over-expression and
cytoplasmic accumulation of cyclin B1 (Figure 4a). Thus,
CD8+ T cells that were primed with DCs loaded with killed
T47D cells were assayed for their capacity to kill cyclin B1
peptide pulsed T2 target cells. As shown in Figure 4b, T2 cells
pulsed with the cyclin B1 peptide were killed efficiently
whereas the control targets, namely T2 cells pulsed with irrel-
evant peptide or natural killer cell sensitive K562 cells, were
killed at a significantly lower (background) level. These results
were obtained with naïve CD8+ T cells from three different
Figure 2
DCs loaded with killed breast cancer cells induce differentiation of effector CTLs DCs loaded with killed breast cancer cells induce differentiation of effector CTLs. CD8+T cells primed, as described in Figure 1, were assessed in a 
standard 51Cr release assay using as targets the HLA-A*0201+ MCF7 cells used to load DCs and NK sensitive K562 cells. (a) CD8+ T cells primed 
by DCs loaded with MCF7 cell bodies exhibit cytotoxic activity against MCF7 used for priming but not against NK sensitive K562 cells. Three sepa-
rate experiments are represented, indicated by different symbols: filled symbols indicate lysis of MCF7 breast cancer cells, and empty symbols indi-
cate lysis of control K562 cells in the same experiment. (b) Cytotoxic activity was blocked by adding anti-MHC class I antibody (HLA-ABC) but not 
by adding relevant isotype control (IgG2a). Each value represents the mean from triplicate wells. Representative of three experiments performed. 
CTL, cytotoxic T lymphocyte; DC, dendritic cell; E:T, effector:target.Available online http://breast-cancer-research.com/content/8/6/R65
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healthy donors and demonstrate successful cross-priming of
antigen specific CTLs by DCs loaded with killed tumor cells.
MUC-1 specific cytotoxic T lymphocytes
T47D cells are also positive for the tumor antigen MUC-1, so
we anticipated that the above cultures primed with T47D-
loaded DCs would also yield T cells specific for MUC-1. This
turned out not to be the case Figure 5a shows that MUC-1
peptide pulsed T2 cells were not killed. Earlier studies by
some of us [25-27] demonstrated that MUC-1 glycoprotein,
which is over-expressed and secreted by breast cancer cells,
is endocytosed by DCs but is mostly retained in early endo-
somes; this leads to its inefficient processing and presentation
to T cells, and hence a lower frequency of MUC-1 specific
effector cells. We assumed that this was responsible for the
low (undetectable) frequency of cross-primed effector CTLs,
Figure 3
Cross-priming of breast cancer specific CTLs Cross-priming of breast cancer specific CTLs. HLA-A*0201+ CTLs were generated as described in Figure 1, except that DCs were loaded with 
(panel a) HLA-A*0201- T47D or (panels b and c) Hs578T breast cancer cells, and CTL activity was tested against HLA-A*0201+ MCF7 breast can-
cer cells, HLA-A*0201+ Me275 melanoma cells and NK cell sensitive K562 cells. (a) DCs loaded with killed HLA-A*0201- T47D breast cancer cells 
induced CTLs that were able to lyse HLA-A*0201+ MCF7 breast cancer cells but not HLA-A*0201+ Me275 melanoma cells or NK cell sensitive 
K562 cells. The y-axis shows the specific lysis, and the x-axis shows the different E:T ratios. Data from four independent experiments are indicated by 
color code. A nonparametric Kruskal-Wallis comparison between the killing of three targets at different E:T ratios was conducted. (b) A similar 
experiment as is summarized in panel a, except CD8+ T cells were primed with DCs loaded with killed Hs578T cells; shown are representatives of 
three experiments. Values are expressed as average and standard deviation of triplicate wells. (c) CD8+ T cells cultured either with cytokines only 
(no DCs), with unloaded DCs (UL), or with DCs loaded with killed Hs578T breast cancer cells (Hs578T) were co-cultured for 24 hours with HLA-
A*0201+ MCF7 breast cancer cells in triplicates. Survival of MCF7 cells (x-axis) was calculated by Trypan blue exclusion. In each case, shown are 
the results of one representative experiment from two performed. CTL, cytotoxic T lymphocyte; DC, dendritic cell; E:T, effector:target; NK, natural 
killer.Breast Cancer Research    Vol 8 No 6    Saito et al.
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and in order to increase further the MUC-1 specific CTL fre-
quency we gave the cultures one additional restimulation with
DCs pulsed with a defined MUC-1 derived peptide. Thus,
naïve CD8+ T cells were primed for 3 weeks with DCs loaded
with killed T47D breast cancer cells, and at day 7, after the
third stimulation, the T cells were restimulated for 5 days with
MUC-1 peptide pulsed autologous DCs. As shown in Figure
5b, T cells given one additional restimulation with peptide-
Figure 4
Cross-priming of cyclin B1 specific CTLs Cross-priming of cyclin B1 specific CTLs.(a) Fluorescence microscopy analysis of cyclin B1 staining with T47D breast cancer cells. No staining with 
isotype control could be seen. (b) CTLs primed as described in Figure 3 killed T2 cells pulsed with cyclin B1 derived CB9 peptide, but not T2 cells 
pulsed with irrelevant (PSA) peptide, indicating the presence of cyclin B1-specific CTLs. Shown are representatives of three experiments. Values are 
expressed as average and standard deviation of triplicate wells. CTL, cytotoxic T lymphocyte; DC, dendritic cell.
Figure 5
Cross-priming of MUC-1 specific CTLs Cross-priming of MUC-1 specific CTLs. After the third stimulation of CD8+ T cells by DCs loaded with killed T47D, CD8+ T cells were stimulated 
with DCs loaded with MUC-1 peptide once and analyzed 5 days after last stimulation. The results of 51Cr release assay show the presence of MUC-
1 specific CD8+ T cells. The percentage cytotoxicity is measured as a function of spontaneous and total release. (a) Lack of killing of target cells 
expressing MUC-1 peptide after 3 weeks of culture with DCs loaded with killed breast cancer cells. (b) Killing of target cells after brief re-stimulation 
of the same cultures with DCs loaded with MUC-1 peptide, indicating the presence of primed T cells. Results are representative of five experiments, 
and each value represents the mean from triplicate wells. CTL, cytotoxic T lymphocyte.Available online http://breast-cancer-research.com/content/8/6/R65
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pulsed DCs were capable of significant lysis of MUC-1 pep-
tide pulsed but not control T2 cells pulsed with irrelevant pep-
tide. Control CD8+ T cells from 3-week cultures primed with
control (not loaded) DCs and restimulated with peptide pulsed
DCs were unable to expand MUC-1 specific T cells in this
assay (<1% specific lysis at an effector:target ratio of 30:1).
Thus, DCs loaded with killed allogeneic breast cancer cells
can also prime (albeit at lower frequency) naïve CD8+ T cells
to differentiate into MUC-1 peptide specific CTLs.
Survivin-specific T cells
To evaluate further the repertoire breadth of elicited CD8+ T
cell immunity, we assessed the priming of CD8+ T cells against
the shared tumor antigen survivin [28-30]. Here, we used
another approach to analyze specificity and effector function
(overlapping peptide libraries and intracytoplasmic IFN-γ stain-
ing), with the intention being to demonstrate priming to many
different peptides derived from the same tumor antigen. Sur-
vivin positive HLA-A*0201+ MCF7 killed breast cancer cells
were used to load DCs. The T cells were assessed using a
recall memory strategy as was used for the MUC-1 specific
responses described above. Our expectation was that T cells
specific for each individual peptide might be present in low fre-
quency. Thus, after priming and boosting with DCs loaded
with killed MCF7 breast cancer cells, the third T cell stimula-
tion was carried out with DCs loaded with the library of over-
lapping 15-mer peptides representing the full length of
survivin. Thereafter, the T cells were briefly (6 hours) restimu-
lated with DCs loaded with survivin derived 15-mer peptides,
stained with anti-IFN-γ mAbs and analyzed by flow cytometry
(Figure 6). As shown in Figure 6, IFN-γ secretion was detected
in T cells exposed to peptides 25 and 26. IFN-γ secreting T
cells are predominantly those that label with anti-CD8 mAbs.
Further analysis demonstrated that peptide 26 contained a 10
amino acid sequence consistent with the previously reported
HLA-A*0201 restricted survivin peptide ELTLGEFLKL [29],
and that peptide 25 contained an eight amino acid sequence
(ELTLGEFL) from this peptide.
Discussion
Using different target antigens and different assays to meas-
ure CTL function, we demonstrated that DCs loaded with
killed allogeneic breast cancer cells cross-prime naïve CD8+ T
cells to differentiate into breast cancer specific effector CTLs.
The elicited CTLs demonstrate specific effector function, as
measured by their capacity to kill breast cancer cells used for
priming, to kill T2 cells pulsed with defined peptides derived
from breast cancer antigens, and to secrete IFN-γ upon pep-
tide exposure. Among the primed CTLs, we demonstrate at
least three specificities against the known shared breast tumor
antigens cyclin B1, MUC-1, and survivin.
Interestingly, we observed differences in the priming of CD8+
T cells with distinct specificities that were consistent with the
unique nature of each antigen. Thus, T cells specific for cyclin
B1 could be detected after priming and two rounds of
boosting with DCs loaded with killed breast cancer cells.
However, this strategy did not permit detection of MUC-1 spe-
cific T cells, which required an additional boost with MUC-1
peptide pulsed DCs. We ascribe this to the differences in effi-
ciency of presentation of different antigens by loaded DCs
and/or differences in the frequency of precursor T cells with
these specificities. Indeed, cyclin B1 represents a protein anti-
gen whose function as a tumor antigen is associated with
increased cytoplasmic accumulation followed by degradation
through ubiquitination [7]. This might make it more accessible
to the DC antigen processing/presentation machinery than the
transmembrane MUC-1 glycoprotein. Previous studies by
some of us [25-27] demonstrated that MUC-1 and HER-2/neu
are retained in DC early endosomes, leading to inefficient
processing and cross-presentation to T cells. These observa-
tions, together with our earlier study and the lack of specificity
to some other defined breast cancer antigens, including HER-
2/neu [23], suggest that efficient cross-presentation of individ-
ual tumor antigens by DCs loaded with killed breast cancer
cells will depend on the nature of these antigens or the form in
which they are taken up by DCs. For example, although we
found that DCs loaded with whole tumor cells are not efficient
in cross-presenting MUC-1, a recent study [31] demonstrated
that loading DCs with breast cancer cell lysates permits more
efficient priming of MUC-1 specific CD8+ T cells. It is difficult
to determine whether the difference in the outcomes between
that study and ours is due to a real difference between loading
DCs with whole tumor cells and loading them with tumor cell
lysate, or to a difference in how the MUC-1 specific T cells
were detected. CD8+ T cells in that report were measured
based on tetramer binding but in our study measurement was
based on a functional assay, specifically the activity of CTLs
against target cells expressing MUC-1 peptide.
Thus, our data offer experimental proof that using DCs loaded
with killed allogeneic breast cancer cells for antigen presenta-
tion leads to priming of T cells to multiple tumor antigens,
some that are already known and could be tested here, and
potentially many more unknown but nevertheless important
shared tumor antigens. The advantage of this approach is the
ability to generate, with one vaccine, T cells specific for many
tumor antigens and in many patients, regardless of HLA type.
Although it is conceivable that part of the generated response
might be due to HLA mismatch, breast cancer tumor antigen
specific immune responses were also generated. Finally, we
previously demonstrated the validity of this approach in
patients with stage IV melanoma [32]. In that study patients
were vaccinated with DCs loaded with killed allogeneic
melanoma cells. We that melanoma specific immune
responses were induced and, perhaps more importantly, dura-
ble (>33 months) objective clinical responses were identified
in 10% of patients in whom conventional therapy failed. Thus,
this vaccination strategy might now be tested in phase I stud-
ies in patients with metastatic breast cancer.Breast Cancer Research    Vol 8 No 6    Saito et al.
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Conclusion
This ability of DCs loaded with killed allogeneic breast cancer
cells to elicit multiantigen specific immunity supports their use
as vaccines in patients with breast cancer.
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